Haynes and Boone is advising BiomX Inc. on the transaction, Cooley is advising Adaptive Phage Therapeutics and Wilmer Cutler Pickering Hale and Dorr is advising the...
BiomX’s Merger with Adaptive Phage Therapeutics
Oragenics’ $2.1 Million Common Stock Offering
Shumaker, Loop & Kendrick advised Oragenics, Inc. on the offering, and Sichenzia Ross Ference Carmel represented ThinkEquity LLC and Laidlaw & Company (UK) Ltd. Oragenics Inc....
Perfect Moment’s $8 Million Initial Public Offering
Mitchell Silberberg & Knupp advised Perfect Moment Ltd. on the offering, and Sichenzia Ross Ference Carmel represented the joint book-running managers. Perfect Moment Ltd. (“Perfect Moment”)...
Viking Therapeutics’s $287.5 Million IPO
Mintz advised the syndicate of underwriters on the deal. Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies...
The NFT Gaming Company’s $7 Million Initial Public Offering
Sheppard, Mullin, Richter & Hampton advised the NFT Gaming Company, while Sichenzia Ross Ference LLP represented Laidlaw & Company (UK) Ltd. in the offering. The NFT...
NLS Pharmaceutics’ $30 Million Purchase Agreement with BVF Partners L.P.
Kellerhals Carrard advised BVF on the deal while Sheppard Mullin served as counsel to Laidlaw & Company (UK) Ltd. NLS Pharmaceutics Ltd. (NASDAQ: NLSP), a Swiss...
Silo Pharma’s $5.75 Million Public Offering and Nasdaq Uplisting
Sichenzia Ross Ference represented Laidlaw & Company (UK) Ltd. în the transaction while Sheppard Mullin advised Silo Pharma. Silo Pharma, Inc. (Nasdaq: SILO) announced the $5.75 million...